Literature DB >> 15063934

[Bone mass regulation by leptin: a hypothalamic control of bone formation].

F Elefteriou1, G Karsenty.   

Abstract

Bone mass is maintained constant between puberty and menopause by the balance between osteoblasts and osteoclasts activity. The existence of a hormonal control of osteoblast activity has been speculated for years by analogy to osteoclast biology. Through the search for such humoral signal(s) regulating bone formation, leptin has been identified as a powerful inhibitor of bone formation. Furthermore, by means of intracerebroventricular infusion of leptin, it has been shown that the effect of this adipocyte-derived hormone on bone is mediated via a brain relay, like all its other functions. Subsequent studies have led to the identification of hypothalamic neurons involved in leptin's antiosteogenic function. In addition, it has been shown that those neurons or neuronal pathways are distinct from neurons responsible for the regulation of energy metabolism. Finally, the peripheral mediator of leptin's antiosteogenic function has been identified as being the sympathetic nervous system. Catecholamine-deficient mice have a high bone mass and sympathomimetics administered to mice decreased bone formation and bone mass. Conversely, beta-blockers increased bone formation and bone mass and blunt the bone loss induced by ovariectomy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063934     DOI: 10.1016/j.patbio.2003.05.006

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

1.  Absence of mechanical loading in utero influences bone mass and architecture but not innervation in Myod-Myf5-deficient mice.

Authors:  Cédric Gomez; Valentin David; Nicola M Peet; Laurence Vico; Chantal Chenu; Luc Malaval; Timothy M Skerry
Journal:  J Anat       Date:  2007-03       Impact factor: 2.610

2.  Female Mice Lacking Estrogen Receptor-α in Hypothalamic Proopiomelanocortin (POMC) Neurons Display Enhanced Estrogenic Response on Cortical Bone Mass.

Authors:  H H Farman; S H Windahl; L Westberg; H Isaksson; E Egecioglu; E Schele; H Ryberg; J O Jansson; J Tuukkanen; A Koskela; S K Xie; L Hahner; J Zehr; D J Clegg; M K Lagerquist; C Ohlsson
Journal:  Endocrinology       Date:  2016-06-02       Impact factor: 4.736

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.